Orion Pharma (DHA:ORIONPHARM) Total Receivables: BDT15,345 Mil (As of Mar. 2026)


DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
71 GF Score
Price BDT30.80
GF Value BDT20.19
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Total Receivables?

Orion Pharma DHA:ORIONPHARM +0.33% 71 Total Receivables is BDT15,345 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.19 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Orion Pharma's Total Receivables for the quarter that ended in Mar. 2026 was BDT15,345 Mil.

Orion Pharma Total Receivables Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Total Receivables Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,401.46 14,905.34 15,896.60 14,476.99 15,046.00

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,410.56 15,046.00 14,956.89 14,950.34 15,345.45
DHA:ORIONPHARM
71GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of BDT15,345 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Total Receivables of BDT15,345 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Total Receivables too high?
Orion Pharma's current Total Receivables is BDT15,345 Mil. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Total Receivables compare to CEG and VST?
Orion Pharma's Total Receivables of BDT15,345 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for an Utilities - Independent Power Producers company?
A good Total Receivables depends on the Utilities - Independent Power Producers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Orion Pharma and its competitors. Orion Pharma's current Total Receivables is BDT15,345 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.19, compared to a current price of BDT30.80 — trading 52.6% above its estimated fair value. The current Total Receivables is BDT15,345 Mil. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Total Receivables is BDT15,345 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.80 is trading 52.6% above its estimated GF Value™ of BDT20.19. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Total Receivables: BDT15,345 Mil
  • GF Value™: BDT20.19 vs. price of BDT30.80 (52.6% above fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score

Get the complete analysis for DHA:ORIONPHARM

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.80
Price
BDT20.19
GF Value